Study summary
Orforglipron brought average HbA1c to about 6.5% in early type 2 diabetes
7.6%weight loss with the highest dose, vs 1.7% with placebo
What was tested
Orforglipron at three doses against placebo for 40 weeks in people with type 2 diabetes managed with diet and exercise only.
What they found
- HbA1c fell by up to 1.48 points vs 0.41 with placebo.
- Weight fell 7.6% with the highest dose vs 1.7%.
- Side effects were mostly mild stomach upset during dose increases.
What it means
Supports orforglipron as an early, oral option.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.